Summary
The hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections of the liver and, if left untreated, can result in fibrosis, permanent liver damage (cirrhosis), HCC, and eventually death. A member of the Flaviviridae viral family and hepacivirus genus, HCV can be classified into six major genotypes, with many additional subtypes within each genotype. While genotype 1 (GT1) causes almost half of HCV infections, all six major genotypes (GT1-6) are prevalent worldwide. The genetic diversity of HCV strains, even within the same host, originates from the low fidelity of the ribonucleic acid (RNA) polymerase, and is thought to account for viral resistance when HCV is treated with a single drug.
Browse Full Report with TOC @ http://www.radiantinsights.com/research/pharmapoint-hepatitis-c-virus-hcv-therapeutics-global-drug-forecast-and-market-analysis-to-2025
During the last few years, the hepatitis C treatment landscape has experienced successive waves of revolutionary change, and is now dominated by high-performance regimens comprising a new generation direct acting antivirals (DAAs). The treatment arsenal has rapidly expanded from only one unsatisfactory option-peginterferon plus ribavirin-to a collection of combination and fixed-dose combination regimens that can cure most patients in as little as 8?12 weeks, many without the use of interferon and/or ribavirin. Currently, these interferon-free and interferon-sparing DAA regimens dominate the treatment landscape as they combine a very high cure rate with improved tolerability and simplified dosing.
Highlights
Key Questions Answered
- Based on interviews with key opinion leaders (KOLs), Radiant Insights has identified key unmet needs in the hepatitis C marketplace.
- What will be the effect of recent and upcoming approval of pan-genotypic DAA regimens?
- How will patient populations develop with changing treatment rates and high cure rates?
- What research and development (R&D) strategies will companies leverage to compete in the future hepatitis C marketplace?
- Which patient population(s) are most likely to be targeted by upcoming pan-genotypic DAA treatment algorithms?
Key Findings
- Radiant Insights estimates that drug sales for hepatitis C in 2015 were approximately $21.7 billion across the 9MM. The global hepatitis C market is expected to experience a steady decline during the forecast period resulting in total sales of $17.5 billion by 2025, translating into a negative Compound Annual Growth Rate (CAGR) of 2.1%. The decline in sales will be most prominent in the US and in France, Germany, and the UK, while the southern European countries, Spain and Italy, as well as China, will see constant or even increasing market sizes during the forecast period.
- The launch of multiple pan-genotypic DAA regimens will provide improved efficacy profiles for difficult-to-treat patients, including patients infected with genotype 3 (GT3), individuals with renal failure, and patients with decompensated liver cirrhosis.
- The main barrier of future growth of the global HCV market will originate from the declining prevalence rates in most countries. Driven by modest treatment rates and excellent cure rates, the patient pools in most countries will steadily decline throughout the forecast; several markets will see significantly reduced total patient pools by 2025.
Scope
- Overview of hepatitis C infections, including epidemiology, etiology, pathophysiology, regional genotype distribution, as well current routine treatment recommendations of all 9MM covered.
- Topline hepatitis C market revenue from 2015-2025. Recent acquisitions, approvals and governmental recommendations and restrictions are included in the forecast model.
- Key topics covered include dynamics in the number of prevalent cases during the forecast, market characterization, unmet needs, and company strategies.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
- Analysis of the current and future market competition in the global hepatitis C marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
See More Reports of This Category by Radiant Insights @ http://www.radiantinsights.com/catalog/pharmaceutical
About Radiant Insights, Inc
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Web: http://www.radiantinsights.com/
The hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections of the liver and, if left untreated, can result in fibrosis, permanent liver damage (cirrhosis), HCC, and eventually death. A member of the Flaviviridae viral family and hepacivirus genus, HCV can be classified into six major genotypes, with many additional subtypes within each genotype. While genotype 1 (GT1) causes almost half of HCV infections, all six major genotypes (GT1-6) are prevalent worldwide. The genetic diversity of HCV strains, even within the same host, originates from the low fidelity of the ribonucleic acid (RNA) polymerase, and is thought to account for viral resistance when HCV is treated with a single drug.
Browse Full Report with TOC @ http://www.radiantinsights.com/research/pharmapoint-hepatitis-c-virus-hcv-therapeutics-global-drug-forecast-and-market-analysis-to-2025
During the last few years, the hepatitis C treatment landscape has experienced successive waves of revolutionary change, and is now dominated by high-performance regimens comprising a new generation direct acting antivirals (DAAs). The treatment arsenal has rapidly expanded from only one unsatisfactory option-peginterferon plus ribavirin-to a collection of combination and fixed-dose combination regimens that can cure most patients in as little as 8?12 weeks, many without the use of interferon and/or ribavirin. Currently, these interferon-free and interferon-sparing DAA regimens dominate the treatment landscape as they combine a very high cure rate with improved tolerability and simplified dosing.
Highlights
Key Questions Answered
- Based on interviews with key opinion leaders (KOLs), Radiant Insights has identified key unmet needs in the hepatitis C marketplace.
- What will be the effect of recent and upcoming approval of pan-genotypic DAA regimens?
- How will patient populations develop with changing treatment rates and high cure rates?
- What research and development (R&D) strategies will companies leverage to compete in the future hepatitis C marketplace?
- Which patient population(s) are most likely to be targeted by upcoming pan-genotypic DAA treatment algorithms?
Key Findings
- Radiant Insights estimates that drug sales for hepatitis C in 2015 were approximately $21.7 billion across the 9MM. The global hepatitis C market is expected to experience a steady decline during the forecast period resulting in total sales of $17.5 billion by 2025, translating into a negative Compound Annual Growth Rate (CAGR) of 2.1%. The decline in sales will be most prominent in the US and in France, Germany, and the UK, while the southern European countries, Spain and Italy, as well as China, will see constant or even increasing market sizes during the forecast period.
- The launch of multiple pan-genotypic DAA regimens will provide improved efficacy profiles for difficult-to-treat patients, including patients infected with genotype 3 (GT3), individuals with renal failure, and patients with decompensated liver cirrhosis.
- The main barrier of future growth of the global HCV market will originate from the declining prevalence rates in most countries. Driven by modest treatment rates and excellent cure rates, the patient pools in most countries will steadily decline throughout the forecast; several markets will see significantly reduced total patient pools by 2025.
Scope
- Overview of hepatitis C infections, including epidemiology, etiology, pathophysiology, regional genotype distribution, as well current routine treatment recommendations of all 9MM covered.
- Topline hepatitis C market revenue from 2015-2025. Recent acquisitions, approvals and governmental recommendations and restrictions are included in the forecast model.
- Key topics covered include dynamics in the number of prevalent cases during the forecast, market characterization, unmet needs, and company strategies.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
- Analysis of the current and future market competition in the global hepatitis C marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
See More Reports of This Category by Radiant Insights @ http://www.radiantinsights.com/catalog/pharmaceutical
About Radiant Insights, Inc
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Web: http://www.radiantinsights.com/
No comments:
Post a Comment